NYBC Ventures Origins
New York Blood Center created NYBC Ventures to accelerate innovation in blood-related fields and cellular therapies and technology. New York Blood Center established the fund with a $50M investment and a mission to improve patients’ lives by advancing therapeutics, enabling platforms and technologies as well as driving collaborations to further NYBC’s impact.
About New York Blood Center
Since its founding more than 60 years ago, the New York Blood Center has provided high-quality, cutting-edge blood products and transfusion services to leading medical institutions in the U.S.
New York Blood Center’s research arm, the Lindsley F. Kimball Research Institute (LFKRI) is one of the world’s preeminent blood research organizations and has paved the way for new blood-related products, techniques, and therapies.
Comprehensive Cell Solutions (CCS), a business unit of New York Blood Center, manufactures cellular therapies for biopharmaceutical companies and academic institutions. CCS is a source for cellular starting material from an unparalleled collection of over 60K units of stem cells and other materials.